Atlas Trials

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Clinical trial NCT05754853 · RECRUITING

Trial details

NCT number
NCT05754853
Sponsor
Shanghai Miracogen Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced or Metastatic Urothelium Cancer
Start date
2023-04-06
Primary completion
2025-10-01
Enrollment
290

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.